Literature DB >> 22511418

Salvage chemotherapy for metastatic germ cell tumours: The known unknowns.

Aaron R Hansen1, Philippe L Bedard.   

Abstract

Entities:  

Year:  2012        PMID： 22511418      PMCID： PMC3328551          DOI： 10.5489/cuaj.12059

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  19 in total

1.  A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

Authors:  G Daugaard; I Skoneczna; N Aass; R De Wit; M De Santis; H Dumez; S Marreaud; L Collette; J R G Lluch; C Bokemeyer; H J Schmoll
Journal:  Ann Oncol       Date:  2010-11-08       Impact factor: 32.976

2.  Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

Authors:  Anja Lorch; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim Margolin; Jean-Pierre Lotz; Jose Ramon Germà-Lluch; Thomas Powles; Christian Kollmannsberger; Jörg Beyer
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

4.  Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours.

Authors:  Michel Beausoleil; D Scott Ernst; Larry Stitt; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

5.  Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.

Authors:  Jean-Pierre Droz; Andrew Kramar; Pierre Biron; José-Luis Pico; Pierre Kerbrat; Jean Pény; Hervé Curé; Christine Chevreau; Christine Théodore; Jeannine Bouzy; Stéphane Culine
Journal:  Eur Urol       Date:  2006-10-27       Impact factor: 20.096

6.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

Authors:  C R Nichols; G Tricot; S D Williams; K van Besien; P J Loehrer; B J Roth; L Akard; R Hoffman; R Goulet; S N Wolff
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

7.  High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

Authors:  W Siegert; J Beyer; I Strohscheer; H Baurmann; H Oettle; J Zingsem; R Zimmermann; C Bokemeyer; H J Schmoll; D Huhn
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

Review 8.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

9.  Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.

Authors:  E R Broun; C R Nichols; P Kneebone; S D Williams; P J Loehrer; L H Einhorn; G J Tricot
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

10.  Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial.

Authors:  Darren R Feldman; Robert Huddart; Emma Hall; Jörg Beyer; Thomas Powles
Journal:  J Cancer       Date:  2011-07-01       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.